The low expression of TNF-α and IL-1β with the use of antibodies is thought to prevent neuronal damage and is expected to prevent the occurrence of Alzheimer’s disease or other cognitive disorders. This evidence concerns the gene IL1B and early-onset autosomal dominant Alzheimer disease.